Pontifax logo

Pontifax

Asia, Tel Aviv, Israel, Herzliya

Description

Pontifax is a venture capital firm that finances pharmaceutical and life sciences companies.

Investor Profile

Pontifax has made 79 investments, with 6 in the past 12 months and 16% as lead.

Stage Focus

  • Series B (29%)
  • Series A (29%)
  • Series C (22%)
  • Series Unknown (8%)
  • Post Ipo Equity (8%)
  • Series D (3%)
  • Seed (1%)
  • Debt Financing (1%)

Country Focus

  • United States (44%)
  • Israel (22%)
  • France (15%)
  • Belgium (6%)
  • Denmark (5%)
  • The Netherlands (3%)
  • United Kingdom (1%)
  • Switzerland (1%)
  • Germany (1%)
  • Spain (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Biopharma
  • Medical Device
  • Life Science
  • Wellness
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Pontifax frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 24
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 5
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 17
Quark Venture
North America, British Columbia, Canada, Vancouver
Co-Investments: 9
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 7
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 7
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 11
HealthCap
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 6
Bpifrance
Europe, Ile-de-France, France, Maisons-alfort
Co-Investments: 9
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 6

Which angels does Pontifax often collaborate with?

PF
North America, Massachusetts, United States, Boston
Shared Deals: 2
AB
North America, California, United States, Los Angeles
Shared Deals: 1
Shmuel Cabilly
Asia, HaMerkaz, Israel, Rehovot
Shared Deals: 1

What are some of recent deals done by Pontifax?

Abcuro

Newton, Massachusetts, United States

Abcuro develops immunotherapies to treat autoimmunity and cancer.

BiotechnologyHealth CareMedicalTherapeutics
Series CFeb 12, 2025
Amount Raised: $200,000,000
Lutris Pharma

Tel Aviv-yafo, Tel Aviv, Israel

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

BiotechnologyFirst AidHealth CareWellness
Series UnknownJan 28, 2025
Amount Raised: $30,000,000
Indapta Therapeutics

San Francisco, California, United States

Indapta Therapeutics is a privately held biotechnology company.

BiopharmaBiotechnologyMedical
Series UnknownDec 17, 2024
Amount Raised: $22,500,000
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series BNov 25, 2024
Amount Raised: $135,000,000
Adcytherix

Marseille, Provence-Alpes-Cote d'Azur, France

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

BiotechnologyOncology
SeedJun 11, 2024
Amount Raised: $32,308,438
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series AMay 29, 2024
Amount Raised: $17,281,921
Eliem Therapeutics

Redmond, Washington, United States

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityApr 11, 2024
Amount Raised: $120,000,000
AgomAb Therapeutics

Ghent, Oost-Vlaanderen, Belgium

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.

BiotechnologyHealth CareTherapeutics
Series COct 11, 2023
Amount Raised: $100,817,696
Abcuro

Newton, Massachusetts, United States

Abcuro develops immunotherapies to treat autoimmunity and cancer.

BiotechnologyHealth CareMedicalTherapeutics
Series BAug 17, 2023
Amount Raised: $155,000,000
ADCendo

Copenhagen, Hovedstaden, Denmark

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.

BiotechnologyHealth Care
Series AApr 4, 2023
Amount Raised: $33,969,252